Novo Nordisk nach Split WKN: A3EU6F ISIN: DK0062498333 Forum: Aktien User: Coronaprofiteur

und das Schöne ist, du bist an bord ! 🤣

Das stimmt :D

https://x.com/i/status/2022333144951599163

Update on $NVO oral Wegovy using both datasets: I shared the Symphony data earlier, where new prescriptions increased from 29,347 to 38,423. Now IQVIA TRx (total prescriptions) also rose from 28,515 to 38,220 in week 5. They measure different things, but both datasets show clearly accelerating adoption.

Phase 2, Ergebnisse müssten jetzt auch dann kommen. *** https://clinicaltrials.gov/study/NCT06409130

Die Pille juckt niemanden mehr, selbst Eli Lilly ist deutlicher im Plus heute

So ein unfähiges Management was die haben das kann nur schief laufen bei Novo Mein persönlicher turnaround Kandidat ist Die Bico Aktie die zieht wieder an 😉 Hoffe das große Comeback kommt bald Weil ich das neue Management von Bico echt klasse finde 👍🏻

Also wenn das durchgeht kann Novo zukünftig jedes Medikament in den USA kopieren unter dem Mantel der Personalisierung.

PERSONALIZED OR NOT? At question is whether Hims' products are sufficiently personalized to be allowable under federal law, which is difficult to ascertain due to a lack of public information about the company's manufacturing and prescription practices, said two attorneys with expertise in FDA regulations.

https://www.reuters.com/legal/litigation/us-could-take-action-including-fines-against-hims-after-brief-wegovy-copy-launch-2026-02-13/

Novos wegovy Pille ist gut bekannt und sehr wirksam. Die Pille von Lilly ist ein neues Molekül, welches bisher nur in Studien an Menschen getestet wurde. Deutlich weniger wirksam als die Wegovy Pille und wer weiß wie gut diese wirklich vertragen wird. Hier hat Novo eindeutig die Nase vorne.

Geiler Einstieg. Da muss Lilly erst einmal herankommen mit der Pille. Trotz der frühen Zulassung wird Novo da bereits sehr gut Kunden akquiriert haben.

Wegovy pill hits warp speed $NVO $LLY The weekly prescription data for the week ending February 6, 2026, has arrived, and it is indeed very strong. The entire GLP-1 complex came back strong, but the underlying trends for Novo are particularly positive. The Oral rocket ship The Wegovy pill continues to be the standout story of Q1. Visible retail volume surged +34% week-over-week to hit 38,220 TRx. Remember, this is just the "visible" portion. We know that the actual run rate (including NovoCare/Telehealth) exceeded 50k last week. With this kind of visible acceleration, the true number is rapidly climbing and market is expanding. Injectables bounce back The negative case last week was that coverage losses would impair the injectable business. The data says otherwise. - Wegovy total: +16.3% (Rebounding from -5.3%) - Injectable only: +13.9% (Excluding the pill) This confirms that the core franchise remains robust. The pill is acting as a massive incremental growth engine, not a cannibalistic one. Market expansion The overall market is healthier than ever. Total starter doses (new patients) hit a new all-time high of 461k TRx. While Lilly captured 36k of that growth (driven by a record 264k vials), Novo captured a very healthy 31k new starters. Summary We are looking at a Novo Nordisk with tailwind. They have stabilized the core injectable business and successfully launched a high-growth oral product that is growing 34% a week. Next catalysts: - Medicare coverage implementation (app. July) - High-dose Wegovy (7.2mg) launch - Continued oral expansion - Decline in volumes from compounders https://x.com/i/status/2022287406892761121

Waren die nicht letztes Mal früher da?

Ja genau 👍 IQVIA